Gu et al.175 found that the combination treatment of cetuximab and cisplatin for NPC cells can downregulate the levels of EGFR, phosphorylated EGFR, and phosphorylated Akt, upregulate the levels of Bax and caspase 3, and inhibit cell growth by increasing cisplatin-induced apoptosis, which indicated that the activation of EGFR/Akt pathway in NPC cells can inhibit the level of apoptosis, causing cisplatin resistance. Here, BAX is linked to nasopharyngeal carcinoma.